Syndax Pharmaceuticals Inc (SNDX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Syndax Pharmaceuticals Inc (SNDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7611
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the treatment of advanced hormone receptor positive and human epidermal growth factor receptor 2 negative breast cancer. Its product candidate is also used for the treatment of non-small cell lung cancer and melanoma, ovarian cancer and other indications. Syndax also develops SNDX-6352, a monoclonal antibody that targets the CSF-1 receptor. The company operates through its offices in Waltham and New York City, the US. Syndax is headquartered in Waltham, Massachusetts, the US.

Syndax Pharmaceuticals Inc (SNDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Syndax Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Syndax Pharma Raises USD80 Million in Series C Financing 13
Syndax Pharma Raises USD23.9 Million in Venture Financing 15
Syndax Pharma Raises USD4.9 Million in Venture Financing 16
Syndax Pharma Raises US$0.05 Million In Venture Financing 17
Syndax Pharma Raises US$27 Million In Series B Venture Financing 18
Partnerships 20
Syndax Pharma Enters into Agreement with Nektar Therapeutics 20
Syndax Pharma Enters into Agreement with AstraZeneca 21
Syndax Pharma Enters into Agreement with Genentech 22
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 23
Merck, Pfizer and Syndax Pharma Enter into Agreement 24
Syndax Pharma Expands its Agreement with Merck 25
Licensing Agreements 26
Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 26
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 27
Kyowa Hakko Kirin Amends Licensing Agreement with Syndax Pharma for Entinostat 28
Syndax Pharma Enters into Licensing Agreement with University of Colorado 30
Syndax Pharma Enters Into Licensing Agreement With Eddingpharm For Entinostat 31
Equity Offering 32
Syndax Pharma to Raise USD25 Million in Private Placement of Shares 32
Syndax Pharma Raises USD52.34 Million in Public Offering of Shares 33
Syndax Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD4.9 Million 35
Syndax Pharmaceuticals Inc – Key Competitors 37
Syndax Pharmaceuticals Inc – Key Employees 38
Syndax Pharmaceuticals Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 07, 2018: Syndax Pharmaceuticals reports second quarter 2018 financial results and provides clinical and business update 40
May 08, 2018: Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update 42
Mar 05, 2018: Syndax Pharmaceuticals Announces Fourth Quarter 2017 Financial Results 44
Nov 07, 2017: Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update 46
Aug 10, 2017: Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update 48
May 08, 2017: Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update 50
Mar 02, 2017: Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update 52
Corporate Communications 54
Sep 25, 2018: Syndax Pharmaceuticals announces board changes 54
Apr 04, 2017: Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors 55
Feb 09, 2017: Syndax Appoints Richard P. Shea as Chief Financial Officer 56
Jan 05, 2017: Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors 57
Product News 58
11/11/2017: Syndax Announces Presentation of Clinical Trial Data on Drug Candidate SNDX-6352 at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting 58
11/07/2017: Syndax to Present Data On Drug Candidate SNDX-6352 at SITC 32nd Annual Scientific Meeting 59
Clinical Trials 60
Apr 13, 2018: Syndax to Present On its Menin-MLL1 targeted inhibitor VTP-50469 at the 2018 American Association for Cancer Research Annual Meeting 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Syndax Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Syndax Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Syndax Pharma Raises USD80 Million in Series C Financing 13
Syndax Pharma Raises USD23.9 Million in Venture Financing 15
Syndax Pharma Raises USD4.9 Million in Venture Financing 16
Syndax Pharma Raises US$0.05 Million In Venture Financing 17
Syndax Pharma Raises US$27 Million In Series B Venture Financing 18
Syndax Pharma Enters into Agreement with Nektar Therapeutics 20
Syndax Pharma Enters into Agreement with AstraZeneca 21
Syndax Pharma Enters into Agreement with Genentech 22
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 23
Merck, Pfizer and Syndax Pharma Enter into Agreement 24
Syndax Pharma Expands its Agreement with Merck 25
Syndax Pharma Enters into Licensing Agreement with Vitae Pharma 26
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 27
Kyowa Hakko Kirin Amends Licensing Agreement with Syndax Pharma for Entinostat 28
Syndax Pharma Enters into Licensing Agreement with University of Colorado 30
Syndax Pharma Enters Into Licensing Agreement With Eddingpharm For Entinostat 31
Syndax Pharma to Raise USD25 Million in Private Placement of Shares 32
Syndax Pharma Raises USD52.34 Million in Public Offering of Shares 33
Syndax Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD4.9 Million 35
Syndax Pharmaceuticals Inc, Key Competitors 37
Syndax Pharmaceuticals Inc, Key Employees 38
Syndax Pharmaceuticals Inc, Other Locations 39

List of Figures
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Syndax Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Syndax Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Syndax Pharmaceuticals Inc (SNDX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Green Dot Corporation
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Med BioGene Inc (MBI)-医療機器分野:企業M&A・提携分析
    Summary Med BioGene Inc (Med BioGene) is a life sciences company, which develops and commercializes genome-based clinical laboratory diagnostic tests. The company’s lead test under development, GeneFx Lung formerly LungExpress Dx, is a proprietary gene expression based test. Its GeneFx Lung test is …
  • Air Products and Chemicals, Inc.:企業の戦略・SWOT・財務情報
    Air Products and Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Air Products and Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sicon Ltd:企業の戦略・SWOT・財務情報
    Sicon Ltd - Strategy, SWOT and Corporate Finance Report Summary Sicon Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Shopper’s Stop Ltd.:企業の戦略・SWOT・財務情報
    Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Silver Bull Resources, Inc.:企業の戦略・SWOT・財務分析
    Silver Bull Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Silver Bull Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Genus Power Infrastructures Ltd (GENUSPOWER):企業の財務・戦略的SWOT分析
    Summary Genus Power Infrastructures Ltd (Genus Power), a subsidiary of Kailash Group, is an electronic equipment manufacturer that develops and distributes electric energy equipment. The company’s products include metering solution products, engineering construction and contracts, solar energy solut …
  • Fenchem Inc:企業の戦略・SWOT・財務分析
    Fenchem Inc - Strategy, SWOT and Corporate Finance Report Summary Fenchem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Myriad Genetics, Inc.:企業の戦略・SWOT・財務情報
    Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Myriad Genetics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Panacea Biotec Ltd (PANACEABIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Panacea Biotec Ltd (Panacea) is a research-based health management company which focuses on manufactures and commercializes pharmaceuticals; biopharmaceuticals; natural, and indigenous products; and vaccines. Its vaccines portfolio includes paediatric vaccines, including trivalent and monova …
  • Eversource Energy (ES):電力:M&Aディール及び事業提携情報
    Summary Eversource Energy (Eversource) is a utility holding company, which operates energy delivery business through its subsidiaries. It transmits and distributes electricity and natural gas. The company sources electricity from its facilities, long-term power supply agreements, and competitive ene …
  • Shoaibi Group-石油・ガス分野:企業M&A・提携分析
    Summary Shoaibi Group (Shoaibi) is a provider of manufacturing, services, product distribution and investment programs. The company offers active venture capital and private equity investments. It offers services such as marketing and technical services, finance and taxation, public relations, admin …
  • Kotak Wealth Management:企業の戦略・SWOT・財務分析
    Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Omron Healthcare Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Omron Healthcare Co Ltd (Omron Healthcare), a subsidiary of Omron Corp, is a provider of medical equipment for health monitoring and therapy. The company offers blood pressure monitors, digital thermometers, body fat meters, pedometers, nebulizers, body composition monitors and electric toot …
  • Brain Tunnelgenix Technologies Corp:医療機器:M&Aディール及び事業提携情報
    Summary Brain Tunnelgenix Technologies Corp (BTT Corp) is a medtech company that develops, manufactures and markets solutions based on the brain thermal tunnel. The company offers various research system, windows based application which provides the sensor data acquisition, data ingestion up to the …
  • Termas De Puyehue S.A.
    Termas De Puyehue S.A. - Strategy, SWOT and Corporate Finance Report Summary Termas De Puyehue S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Smurfit Kappa Group plc:企業の戦略・SWOT・財務情報
    Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report Summary Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Celtaxsys Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Celtaxsys Inc (Celtaxsys) is a clinical-stage pharmaceutical development company that develops novel foundational therapies to treat inflammation in rare, orphan designated diseases. Oral once daily acebilustat, the company’s flagship drug candidate under phase 2 clinical trial, is intended …
  • Crisil Ltd (CRISIL):企業の財務・戦略的SWOT分析
    Summary Crisil Ltd (Crisil), a subsidiary of S&P Global Inc is a financial service provider that offers risk management services. The company provides ratings, research and risk and policy advisory services. It offers services such as credit ratings, business school gradings, real estate star rating …
  • Lojas Renner S.A.:企業の戦略・SWOT・財務情報
    Lojas Renner S.A. - Strategy, SWOT and Corporate Finance Report Summary Lojas Renner S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆